A Whole-Person Perspective
For some individuals, depression does not improve despite trying multiple
antidepressants and therapies. This is known as treatment-resistant depression
(TRD) — a condition that can feel frustrating, exhausting, and isolating.
Spravato® (esketamine), an FDA-approved nasal spray, offers a new pathway to
relief for adults with TRD and for those experiencing major depressive disorder
(MDD) with suicidal thoughts or actions. Unlike traditional antidepressants, Spravato
works on different brain pathways and can provide rapid improvement in mood for
many patients.
At Integrative Psychiatric Services (IPS), we provide Spravato within a
comprehensive treatment plan, combining clinical expertise with compassionate care
in a safe, supportive setting.
Spravato in America: Fast Facts
How Spravato Works
Spravato targets the NMDA receptor system in the brain, increasing glutamate — a
neurotransmitter involved in mood regulation and neuroplasticity. This action can:
Who is Spravato For?
Spravato may be considered for adults who:
The Spravato Process at IPS
We provide Spravato in a comfortable, private, and medically monitored
environment:
Because Spravato can cause temporary side effects such as dizziness or feeling
“spaced out,” you will need a ride home after each session.
Typical Treatment Schedule
Possible Side Effects
Most side effects are temporary and monitored closely during each session:
Why Choose IPS for Spravato?
Moving Forward with Hope
Treatment-resistant depression can feel like a closed door, but Spravato offers a new
way forward. Many patients describe feeling their mood lift for the first time in years.
At IPS, we’re committed to guiding you through every step — with science-based
care, compassion, and a shared belief that recovery is possible
Visited 84 times, 1 visit(s) today